In theory, a small molecule inhibitor of endosomal recycling could be employed to divert internalised PD-L1 into the degradative pathway, thus reducing the amount of PD-L1 at the cell surface and downregulating the ability of the tumour cells to inhibit CD8+ T cells. Here, CD8A is linked to neoplasm.